Celebrex Label Adds Cardiovascular Risk Language
This article was originally published in The Pink Sheet Daily
Executive Summary
Celecoxib labeling revision includes long-term safety data from three celecoxib trials, one of which suggests increased cardiovascular risk. Celebrex also gains ankylosing spondylitis indication.